Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes
Authors:
- Ko-Ichi KawaharaKKKo-Ichi Kawahara
- Kohji OkamotoKOKohji Okamoto
- Shingo YamadaSYShingo Yamada
- Minetsugu YasudaMYMinetsugu Yasuda
- Hitoshi ImaizumiHIHitoshi Imaizumi
- Yuko NawaYNYuko Nawa
- Xiaojie MengXMXiaojie Meng
- Binita ShresthaBSBinita Shrestha
- Teruto HashiguchiTHTeruto Hashiguchi
- Ikuro MaruyamaIMIkuro Maruyama
- 1 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 28 (10) , 1825-1830
Abstract
Objective— High mobility group box 1 protein (HMGB1) was identified as a mediator of endotoxin lethality. We previously reported that thrombomodulin (TM), an endothelial thrombin-binding protein, bound to HMGB1, thereby protecting mice from lethal endotoxemia. However, the fate of HMGB1 bound to TM remains to be elucidated. Methods and Results— TM enhanced thrombin-mediated cleavage of HMGB1. N-terminal amino acid sequence analysis of the HMGB1 degradation product demonstrated that thrombin cleaved HMGB1 at the Arg10-Gly11 bond. Concomitant with the cleavage of the N-terminal domain of HMGB1, proinflammatory activity of HMGB1 was significantly decreased ( P Conclusions— TM not only binds to HMGB1 but also aids the proteolytic cleavage of HMGB1 by thrombin. These findings highlight the novel antiinflammatory role of TM, in which thrombin-TM complexes degrade HMGB1 to a less proinflammatory form.Keywords
This publication has 40 references indexed in Scilit:
- The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanismJournal of Clinical Investigation, 2005
- High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenalNature Reviews Immunology, 2005
- Reversing established sepsis with antagonists of endogenous high-mobility group box 1Proceedings of the National Academy of Sciences, 2003
- The immunopathogenesis of sepsisNature, 2002
- HMGB1 as a Late Mediator of Lethal Systemic InflammationAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learnedCritical Care Medicine, 2001
- HMG-1 as a Late Mediator of Endotoxin Lethality in MiceScience, 1999
- Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis SyndromeJAMA, 1994
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemiaNature, 1987